Cleland J G, Dargie H J, Robertson J I
Br J Clin Pharmacol. 1984;18 Suppl 2(Suppl 2):157S-160S. doi: 10.1111/j.1365-2125.1984.tb02593.x.
Captopril, the first orally effective converting enzyme inhibitor, was administered to 14 patients with chronic heart failure for 6 week periods, in a double-blind crossover comparison with placebo. Captopril improved symptoms and exercise performance, while left ventricular internal dimensions were reduced. The fall in blood pressure induced by captopril was well tolerated. Glomerular filtration rate was reduced and effective renal plasma flow increased on captopril. No decline in body weight or total body sodium was seen, suggesting that a natriuresis had not occurred. Serum and total body potassium rose. Ventricular arrhythmias declined.
卡托普利是第一种口服有效的血管紧张素转换酶抑制剂，对14例慢性心力衰竭患者进行了为期6周的给药治疗，并与安慰剂进行双盲交叉对照比较。卡托普利改善了症状和运动能力，同时左心室内径减小。卡托普利引起的血压下降耐受性良好。使用卡托普利时肾小球滤过率降低，有效肾血浆流量增加。体重和全身钠含量未见下降，表明未发生利钠作用。血清钾和全身钾含量升高。室性心律失常减少。
